LA JOLLA PHARMACEUTICAL CO Form 8-K June 03, 2005

# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

June 2, 2005


# La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

Delaware	0-24274	33-0361285
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
6455 Nancy Ridge Drive, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area code:		(858) 452-6600
	Not Applicable	
Former n	name or former address, if changed since last rep	port

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
ſ	1	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



On June 2, 2005, the Company issued a press release announcing that Steven Engle, the Company's Chief Executive Officer, would present at the Pacific Growth Equities Life Sciences Growth Conference on June 8, 2005. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

#### Item 9.01. Financial Statements and Exhibits.

(c) Exhibits. The following exhibits are filed with this report on Form 8-K:

Exhibit Number Description of Exhibit 99.1 Press Release, dated June 2, 2005

#### Top of the Form

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

June 2, 2005 By: /s/ Steven B. Engle

Name: Steven B. Engle

Title: Chairman and Chief Executive Officer

### Top of the Form

### Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated June 2, 2005